Rustam Salimkhanov

Dr. Rustam Salimkhanov

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Ilya Viktorovich DmitrievIlya Viktorovich Dmitriev
Ilya Viktorovich Dmitriev
ASAnastasia Severina
Anastasia Severina
NZNikita S. Zhuravel
Nikita S. Zhuravel
MYMadina I. Yevloyeva
Madina I. Yevloyeva
RSRustam Salimkhanov
Rustam Salimkhanov
MSMarina Shestakova
Marina Shestakova
Simultaneous pancreas–kidney transplantation (SPKT) can improve long-term patient survival and restore endogenous insulin secretion in recipients with type 1 diabetes (T1D). There are currently few data on glucose fluctuations assessed by continuous glucose monitoring (CGM) after SPKT. Aim: to evaluate CGM-derived time in range (TIR) and glucose variability (GV) in patients with T1D and functioning pancreatic grafts after SPKT. Fifty-four CGM recordings from 43 patients, 15 men and 28 women, aged 34 (31; 39) years were analyzed. Time since SKPT was up to 1 year (group 1, n = 13), from 1 to 5 years (group 2, n = 15), and from 5 to 12 years (group 3, n = 26). TIR (3.9–10 mmol/L), Time Above Range (TAR), Time Below Range (TBR), and GV parameters were estimated. There were no differences in mean glucose (5.5 [5.1; 6.2], 5.9 [5.4; 6.2], and 5.9 [5.6; 6.7] mmol/L), TIR (97.6 [92.8–99.1], 97.2 [93.2; 99.1], and 97.5 [93.4; 99]%); TAR (0, 1.8 [1.3; 3.7], and 2.5 [2; 5]%), TBR (5 [3.3; 12.7], 4.1 [2.2; 10.1], and 3.5 [1.3; 6.5]%) and GV parameters between three groups (all p > 0.05). Thus, recipients with functioning pancreatic grafts demonstrate remarkably high TIR and low GV after SPKT.

5 January 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
RSRustam Salimkhanov
Rustam Salimkhanov
EBEkaterina Bondarenko
Ekaterina Bondarenko
AEAnna Eremkina
Anna Eremkina
EBEkaterina Bibik
Ekaterina Bibik
EKEkaterina Kim
Ekaterina Kim
NMNatalia Mokrysheva
Natalia Mokrysheva
Sagliker syndrome (SS) is an extremely rare disorder that manifests in patients with advanced chronic kidney disease (CKD) undergoing programmed hemodialysis as a renal replacement therapy. Treatment of secondary hyperparathyroidism (SHPT) in these patients is still challenging. The main clinical manifestations of SS include craniofacial and fingertip deformities, dental anomalies, gingival hyperplasia, short stature, hearing loss, neurological and psychiatric impairment. The etiology and pathogenesis of SS in patients with SHPT require further clarification. However, mutations in the GNAS1, FGF23, and FGFR3 genes were described in some patients, suggesting a possible role of genetic predisposition to the syndrome. The preferred therapeutic approach for SS is surgery, but the volume of the operation is debated. The main surgical strategies include total, subtotal parathyroidectomy, or total parathyroidectomy with autotransplantation of the parathyroid gland (PG). Unfortunately, parathyroidectomy does not contribute to the regression of significant skeletal deformities. We present a unique clinical case of a patient with classical features of SS, recurrent tertiary hyperparathyroidism (THPT) after total parathyroidectomy due to intrathyroidal parathyroid carcinoma (PC).

26 January 2023 in Genes
Verified
Journal Article
Open access
PDF file
AGAnna Gorbacheva
Anna Gorbacheva
TPTatyana Pogoda
Tatyana Pogoda
VBViktor Bogdanov
Viktor Bogdanov
VZVictoriya Zakharova
Victoriya Zakharova
RSRustam Salimkhanov
Rustam Salimkhanov
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Pseudohypoparathyroidism (PHP) is a heterogeneous orphan disease characterized by multihormonal resistance and several phenotypic features. In some cases, PHP is caused by a mutation in the GNAS that encodes the alpha subunit of the G protein, one of the key transmitters of intracellular signals. A correlation between the genotype and phenotype of patients with GNAS mutations has not yet been described. This often makes diagnosis, drug prescription, and timely diagnosis difficult. Information about GNAS functioning and the impact of specific mutations on the clinical course of the disease is limited. Establishing of the pathogenicity by newly identified GNAS mutations will expand the understanding of this gene functioning in the cAMP signaling pathway and may become the basis for personalized treatment. This paper provides a clinical description of a patient with the Ia PHP phenotype caused by a previously unknown mutation in GNAS (NC_000020.11(NM_000516.7)): c.719-29_719-13delinsACCAAAGAGAGCAAAGCCAAG in the heterozygous state. Verification of the pathogenicity of the detected mutation is also described.

20 February 2020 in Kuban Scientific Medical Bulletin
Verified
Journal Article
Open access
PDF file
RSRustam Salimkhanov
Rustam Salimkhanov
VSVladislav R. Sharifullin
Vladislav R. Sharifullin
YKYulia R. Kushnareva
Yulia R. Kushnareva
AKAzamat Kh. Kade
Azamat Kh. Kade
PPPavel P. Polyakov
Pavel P. Polyakov
This article presents a review of available information on asprosin — a hormone of white adipose tissue discovered in 2016. The history of its discovery, as well as its action mechanisms and main targets are examined. Changes in the plasma level of asprosin under some pathological conditions are analysed. The importance of studying asprosin is determined by its functions: asprosin regulates physiological processes during fasting and plays an important role in the development of metabolic disorders, such as insulin resistance. There are relatively few studies concerned with asprosin; however, this hormone can already be considered as a diagnostic marker and a potential target in the treatment of certain metabolic disorders, e.g. diabetes mellitus and obesity.

11 November 2022 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
ATA. A. Trukhin
A. A. Trukhin
VYVasiliy Yartsev
Vasiliy Yartsev
MSM. S. Sheremeta
M. S. Sheremeta
DYD. V. Yudakov
D. V. Yudakov
MKM. O. Korchagina
M. O. Korchagina
SGS. V. Grishkov
S. V. Grishkov
Вторичная облитерация слезоотводящих путей при проведении радиойодтерапии 131 I дифференцированного рака щитовидной железы

15 August 2024 in Clinical and experimental thyroidology
Verified
Journal Article
Open access
PDF file
EKElena Kovaleva
Elena Kovaleva
RSRustam Salimkhanov
Rustam Salimkhanov
AEA. R. Elfimova
A. R. Elfimova
AEAnna Eremkina
Anna Eremkina
APAnastasiia Pershina-Miliutina
Anastasiia Pershina-Miliutina
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
BACKGROUND. Chronic hypoparathyroidism (HypoPT) is a relatively rare endocrine disorder. Adequate control of the disease requires the prescription of lifelong multicomponent therapy. Lack of sustained compensation of HypoPT is associated with the development of both early and delayed complications, including functional and structural renal pathology, cataracts, cerebral calcification, cardiac rhythm and/or conduction disorders, and others.AIM. To study the associations of clinical, laboratory and instrumental parameters, as well as the medical therapy, with long-term complications of chronic HypoPT.MATERIALS AND METHODS. The observational, continuous study was based on the data of the Russian Registry of Patients with Chronic Postoperative and Nonsurgical HypoPT; 1776 patients from 81 regions of the Russian Federation were included in the study.RESULTS. In the study population, 26,3% of patients (n=467) had at least one of the HypoPT complications, among them nephrolithiasis/nephromicrolithiasis was diagnosed in 33,4%. Nephrocalcinosis was observed in 10,7% and was more often bilateral (93,5%). In 17,4% of patients there was a significant decrease in GFR, corresponding to CKD stages 3a-5. Cataract was present in 34,7% of patients with chronic HypoPT. Statistically significant associations were found for disease duration with impaired renal filtration function (p<0,001), nephrocalcinosis/nephrolithiasis (p=0,001) and cataract (p<0,001). Patients with impaired renal function had higher serum ionized calcium level (p=0,0071) and lower phosphorus level (p=0,002). Cataract was predominantly diagnosed in patients of older age group (p<0,001), predominant in the presence of hypocalcemia by ionized calcium level (p=0,001). In patients undergoing brain MSCT for neurological symptoms, basal ganglia calcifications were detected in more than half of the cases (56,2%). Brain calcification was associated with younger patient age (p<0,001), hyperphosphatemia (p<0,001), hypomagnesemia (p=0,010). Statistically significant associations were observed between calcification of brain structures and higher doses of alfacalcidol and calcium carbonate (p=0,007).CONCLUSION. The analysis of the database revealed a number of associations between clinical, laboratory and instrumental parameters and long-term complications of HypoPT. The most significant factors in the development of renal pathology and cataracts are the duration of the disease, as well as off-target indicators of calcium-phosphorus metabolism.